|
66 Companies |
|
64 Products |
|
64 Products |
|
38 Mechanisms of Action |
|
0 Trials |
|
1523 News |
|
| «12...19202122232425262728293031» |
- FluMist (influenza vaccine, live, intranasal) / AstraZeneca, FluMist Quadrivalent (live attenuated influenza vaccine nasal spray) / AstraZeneca, Daiichi Sankyo
New P1 trial: Safety of Lactobacillus Rhamnosus GG Versus Placebo in Elderly Subjects Receiving Live Attenuated Influenza Vaccine (clinicaltrials.gov) - Mar 4, 2012
P1, N=30, Completed, Sponsor: Patricia L. Hibberd
- ||| Dectova (zanamivir) / GSK
Enrollment closed: Safety Study to Assess IV Zanamivir for Treatment of Influenza Infection in Patients Who Are in Hospital (clinicaltrials.gov) - Feb 29, 2012
P2, N=190, Active, not recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting
- ||||||| Trial completion: Immunogenicity and Safety Study to Assess Influenza Vaccine Formulated With Haemagglutinin (HA) Antigen From Two Different Suppliers (clinicaltrials.gov) - Feb 29, 2012
P3, N=440, Completed, Sponsor: Crucell Holland BV
Recruiting --> Active, not recruiting Recruiting --> Completed
- Fluzone (influenza vaccine) / Sanofi
Trial completion: Systems Biology of Trivalent Influenza Vaccine (TIV) in Young and Elderly (clinicaltrials.gov) - Feb 29, 2012
P=N/A, N=66, Completed, Sponsor: Emory University
Recruiting --> Completed Active, not recruiting --> Completed
- Trial completion: Booster Trial to 07-0019 With A/Anhui/05 With and Without MF59 (clinicaltrials.gov) - Feb 29, 2012
P1, N=637, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| oseltamivir / Generic mfg.
Enrollment change: A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants. (clinicaltrials.gov) - Feb 27, 2012
P3, N=166, Recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed N=250 --> 166
- ||||||| Fluzone (influenza vaccine) / Sanofi
Trial completion: Study of Quadrivalent Influenza Vaccine Among Children (clinicaltrials.gov) - Feb 27, 2012
P3, N=4363, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
N=250 --> 166 Active, not recruiting --> Completed
- Fluzone (influenza vaccine) / Sanofi
Trial completion: 2010-2011 Trivalent Influenza Vaccine (TIV) in Pregnant Women (clinicaltrials.gov) - Feb 22, 2012
P2, N=183, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion: Cellular and Humoral Immune Response to Primary and Secondary Immunization With Subvirion H5N1 Vaccines (clinicaltrials.gov) - Feb 15, 2012
P1, N=95, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Trial initiation date: CAIVT: Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine (CAIV-T) in Healthy Children (clinicaltrials.gov) - Feb 14, 2012
P2, N=173, Completed, Sponsor: MedImmune LLC
Active, not recruiting --> Completed Initiation date: Jun 2001 --> Sep 2001
- ||| Enrollment change: CAIVT: Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine (CAIV-T) in Healthy Children (clinicaltrials.gov) - Feb 14, 2012
P2, N=173, Completed, Sponsor: MedImmune LLC
Initiation date: Jun 2001 --> Sep 2001 N=240 --> 173
- New P1 trial: Evaluating the Safety and Immune Response of an H7N7 Vaccine in Healthy Adults (clinicaltrials.gov) - Feb 14, 2012
P1, N=45, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- |||||||||| Naphcon-A (naphazoline HCl) / Novartis, Alervil (pheniramine maleate) / Incepta
New P3 trial: Efficacy of Nasal Naphazoline Hydrocloride + Pheniramine Maleate + Panthenol Compared With Naphazoline Hydrocloride in the Symptomatic Control of Nasal Congestion and Nasopharyngeal (clinicaltrials.gov) - Feb 13, 2012
P3, N=212, Active, not recruiting, Sponsor: EMS
- |||| Trial completion: Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two Monovalent H5N1 Influenza Vaccines Containing 2 Doses of H5N1 Influenza Antigen, in Non-elderly Adult and Elderly Subjects (clinicaltrials.gov) - Feb 7, 2012
P2, N=722, Completed, Sponsor: Novartis Vaccines
N=240 --> 173 Active, not recruiting --> Completed
- || Vaxigrip (inactivated influenza vaccine (split virion)) / Sanofi
New P3 trial: Immunogenicity and Safety of Different Dosing Schedules of Trivalent Influenza Vaccine in HIV-infected Pregnant Women (clinicaltrials.gov) - Feb 5, 2012
P3, N=789, Active, not recruiting, Sponsor: University of Witwatersrand, South Africa
- | Trial completion: Safety and Reactogenicity of a Monovalent Conjugated Vaccine Against Haemophilus Influenzae Type b (clinicaltrials.gov) - Feb 5, 2012
P1, N=40, Completed, Sponsor: Novartis Vaccines
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| Trial completion: TERIVA: Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide (clinicaltrials.gov) - Feb 2, 2012
P2, N=128, Completed, Sponsor: Sanofi
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Dectova (zanamivir) / GSK
New P3 trial: A Study of Intravenous Zanamivir in the Treatment of Hospitalized Patients With Influenza Infection (clinicaltrials.gov) - Feb 2, 2012
P3, N=21, Completed, Sponsor: GlaxoSmithKline
- Enrollment change: Clinical Validation of the Point-of-Care MSD Influenza Test (clinicaltrials.gov) - Jan 29, 2012
P=N/A, N=391, Terminated, Sponsor: Meso Scale Diagnostics, LLC.
Active, not recruiting --> Completed N=1000 --> 391
- Trial completion: FluBAL: Immuno-virological Characterization of Severe H1N1v Influenza Infection in Bronchoalveolar Lavage (clinicaltrials.gov) - Jan 26, 2012
P=N/A, N=30, Completed, Sponsor: Institut National de la Sant
N=1000 --> 391 Recruiting --> Completed
- ||||||| Infanrix (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) / GSK
Trial completion: Immunogenicity and Safety Study of Booster Dose of GSK Biologicals' IPV (Poliorix™) and DTPa/Hib (Infanrix+Hib™) Vaccine (clinicaltrials.gov) - Jan 25, 2012
P3, N=831, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Completed Active, not recruiting --> Completed
- ||||||| FluLaval Quadrivalent (influenza vaccine) / GSK
Trial completion: A Study to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine in Children (clinicaltrials.gov) - Jan 25, 2012
P3, N=5168, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| ASP7373 / Shionogi
Trial completion: A Study to Evaluate the Immune Response to the ASP7373 and Its Safety in Healthy Adult Volunteers (clinicaltrials.gov) - Jan 22, 2012
P2, N=180, Completed, Sponsor: Astellas Pharma Inc
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| Flublok (influenza vaccine) / Sanofi, Ildong, Shionogi
Trial completion: A Study to Evaluate the Immune Response to the ASP7374 and Its Safety in Healthy Adult Volunteers (clinicaltrials.gov) - Jan 22, 2012
P1/2, N=165, Completed, Sponsor: Astellas Pharma Inc
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Enrollment change: Immunogenicity and Safety Following a Single Dose of Influenza Vaccines in Healthy Children Who Received Either One or the Other Vaccine (an Adjuvanted Sub-unit Influenza Vaccine and a Non-adjuvanted Split Virion Influenza Vaccine) in the Previous V70P2 Study (clinicaltrials.gov) - Jan 22, 2012
P2, N=89, Completed, Sponsor: Novartis Vaccines
Active, not recruiting --> Completed N=244 --> 89
- |||| Trial completion: Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2011-2012 (clinicaltrials.gov) - Jan 22, 2012
P2, N=63, Completed, Sponsor: Novartis Vaccines
N=244 --> 89 Active, not recruiting --> Completed
- ||||||| Trial completion: Immunogenicity and Safety of V70P5 Revaccination Subjects (clinicaltrials.gov) - Jan 22, 2012
P3, N=197, Completed, Sponsor: Novartis Vaccines
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | New P4 trial: The Safety and Immune Response to Influenza Vaccination in Pregnant Women (clinicaltrials.gov) - Jan 19, 2012
P4, N=46, Completed, Sponsor: Adimmune Corporation
- |||| Trial completion: Immunogenicity and Safety of AdimFlu-S, Formulation 2010-2011, in Infants Aged Between 6-12months Old (clinicaltrials.gov) - Jan 18, 2012
P4, N=59, Completed, Sponsor: Adimmune Corporation
Active, not recruiting --> Completed Recruiting --> Completed
- ||| Trial completion: Immunogenicity and Safety of Influenza Virus Vaccine, AdimFlu-S (A/H1N1), in Pediatric Population (clinicaltrials.gov) - Jan 18, 2012
P=N/A, N=183, Completed, Sponsor: Adimmune Corporation
Recruiting --> Completed Active, not recruiting --> Completed
- ||| Trial completion: Immunogenicity and Safety of Influenza Virus Vaccine, AdimFlu-S (A/H1N1), in Adults and Elders (clinicaltrials.gov) - Jan 18, 2012
P=N/A, N=292, Completed, Sponsor: Adimmune Corporation
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| New P4 trial: Phase IV Clinical Trial of an Inactivated Influenza Split Vaccine (clinicaltrials.gov) - Jan 17, 2012
P4, N=6000, Completed, Sponsor: Hualan Biological Engineering, Inc.
- New P1 trial: Safety Trial of Live Attenuated Influenza (H7N3) Vaccine (clinicaltrials.gov) - Jan 16, 2012
P1, N=40, Completed, Sponsor: Program for Appropriate Technology in Health
- |||| Infanrix Hexa (diphtheria tetanus toxoids, acellular pertussis, hepatitis B (recombinant), inactivated poliomyelitis, adsorbed conjugated Haemophilus influenzae type b vaccine) / GSK
Trial completion: Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744) (clinicaltrials.gov) - Jan 12, 2012
P2, N=721, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Safety Study of Flufirvitide-3 Nasal Spray in Healthy Subjects (clinicaltrials.gov) - Jan 12, 2012
P1, N=32, Completed, Sponsor: Autoimmune Technologies, LLC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- New P1 trial: Safety Trial of Monovalent Whole Virus Influenza (H1N1) Vaccine (clinicaltrials.gov) - Jan 9, 2012
P1, N=48, Completed, Sponsor: Program for Appropriate Technology in Health
- Trial completion: Group Study of the Safety of and Immune Response to a Single Dose of Bird Flu Vaccine (H7N3) in Healthy Adults (clinicaltrials.gov) - Jan 8, 2012
P1, N=20, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Recruiting --> Completed
- | New P4 trial: MUCOFLU: Cohort Study Evaluating the Clinical Effectiveness, Safety and Immunogenicity to the Pandemic Influenza Vaccination (clinicaltrials.gov) - Dec 22, 2011
P4, N=458, Active, not recruiting, Sponsor: Assistance Publique - H
- ||| New P1 trial: Seasonal Influenza DNA Vaccine Prime With Trivalent Inactivated Vaccine (TIV) Boost Compared to TIV Alone (clinicaltrials.gov) - Dec 21, 2011
P1, N=131, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- Trial completion: Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Monovalent Pandemic H5N1 Vaccine in Adults (clinicaltrials.gov) - Dec 20, 2011
P2, N=78, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Fluzone (influenza vaccine) / Sanofi
Trial completion: Study of Quadrivalent Influenza Vaccine Among Adults (clinicaltrials.gov) - Dec 20, 2011
P3, N=739, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| New P2 trial: Immunogenicity and Safety of an Inactivated Split-virion 2009 Pandemic Influenza A H1N1 Vaccine in Infants (clinicaltrials.gov) - Dec 14, 2011
P2, N=312, Completed, Sponsor: Shanghai Institute Of Biological Products
- ||||| Rapivab (peramivir) / BioCryst
Enrollment change: Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza (clinicaltrials.gov) - Dec 13, 2011
P3, N=234, Completed, Sponsor: BioCryst Pharmaceuticals
Active, not recruiting --> Completed N=300 --> 234
- Trial completion: An Open-Label, Randomized Phase I Study in Healthy Adults of the Safety and Immunogenicity of Prime-Boost Intervals With Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005 (Sanofi Pasteur, Inc.) Administered Alone or Following Re... (clinicaltrials.gov) - Dec 13, 2011
P1, N=64, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=300 --> 234 Active, not recruiting --> Completed
- Rapivab (peramivir) / BioCryst
Trial termination: A Study to Evaluate the Efficacy and Safety of Intravenous Peramivir in Subjects With Uncomplicated Influenza. (clinicaltrials.gov) - Dec 12, 2011
P3, N=1, Terminated, Sponsor: BioCryst Pharmaceuticals
Active, not recruiting --> Completed Suspended --> Terminated; This study was terminated for administrative reasons
- Rapivab (peramivir) / BioCryst
Enrollment change: A Study to Evaluate the Efficacy and Safety of Intravenous Peramivir in Subjects With Uncomplicated Influenza. (clinicaltrials.gov) - Dec 12, 2011
P3, N=1, Terminated, Sponsor: BioCryst Pharmaceuticals
Suspended --> Terminated; This study was terminated for administrative reasons N=1200 --> 1
- ||||| Pentacel (diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and hemophilus b conjugate) / Sanofi
New P4 trial: Safety of PENTAXIM® Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China (clinicaltrials.gov) - Dec 11, 2011
P4, N=900, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
- ||||||| Trial completion: A Study of DTaP//PRP-T Combined Vaccine (ACTACEL) Versus Local DTaP and Act-HIB Monovalent Vaccine in Healthy Infants (clinicaltrials.gov) - Dec 11, 2011
P3, N=1056, Completed, Sponsor: Sanofi
N=1200 --> 1 Active, not recruiting --> Completed
- FluMist (influenza vaccine, live, intranasal) / AstraZeneca, FluMist Quadrivalent (live attenuated influenza vaccine nasal spray) / AstraZeneca, Daiichi Sankyo
New P1 trial: Immunogenicity and Safety of Live Attenuated Influenza Vaccine (Flumist) Administered by Nasal and Sublingual Route (clinicaltrials.gov) - Dec 6, 2011
P1, N=40, Completed, Sponsor: International Vaccine Institute
- |||| Trial completion: Safety and Immunogenicity of One Dose of an Inactivated Trivalent Sub-unit Influenza Vaccine Administered to Non-elderly Adult and Elderly Subjects (clinicaltrials.gov) - Dec 5, 2011
P2, N=125, Completed, Sponsor: Novartis Vaccines
Active, not recruiting --> Completed Not yet recruiting --> Completed